Global pharmaceutical industry media Fierce Pharma has recently unveiled the annual "Fierce 50 of 2025" lists. Akeso Inc, an enterprise based in Zhongshan's Torch High-tech Zone, stood out as the sole Chinese biopharmaceutical company in the Breakthrough category, honored for its groundbreaking work in tumor immunotherapy and its transformative influence on global treatment paradigms. 

The company shares this hallmark list for the global pharmaceutical sector with industry titans like Pfizer, Gilead and Alnylam, along with top scholars such as Dr Steven McCarroll from the Broad Institute of MIT and Harvard.

Headquartered in Torch High-tech Zone, Akeso was established in 2012 at the National Health Technology Park. It has evolved from a locally nurtured biopharmaceutical firm into a global benchmark. Currently, Akeso boasts over 50 innovative drug candidates with independently owned global intellectual property rights, including 25 in clinical trials, and 7 Category-1 new drugs that have been approved for the market.